Development and Validation of Risk Stratification for Heart Failure After Acute Coronary Syndrome Based on Dynamic S100A8/A9 Levels
Journal of the American Heart Association · 04.02.2025 · 14 (3)
DOI: 10.1161/jaha.124.037401 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 04.02.2025. Verfasst von Jie Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital of Capital Medical University Beijing China. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Calgranulin A, Calgranulin B, Heart Failure. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background The early assessment of heart failure (HF) risk in patients with acute coronary syndrome (ACS) can help reduce mortality. S100A8/A9 is not only rapidly released after myocardial ischemia, but is also involved in reperfusion injury, which is an important predictor of HF after ACS. We attempted to construct a reliable HF risk stratification tool for evaluating patients with ACS after reperfusion therapy based on S100A8/A9 dynamic changes. Methods and Results This prospective study included 3 independent cohorts of patients with ACS who received reperfusion therapy. The discovery cohort was divided into 2 subgroups: the longitudinal subgroup (n=264) with serum S100A8/A9 levels measured at admission and on days 1, 2, 3, and 4 postadmission, respectively, and the 2‐point subgroup (n=798) with S100A8/A9 levels measured at admission and on day 1 postadmission, respectively. Validation cohorts 1 (n=1399) and 2 (n=1183) both had S100A8/A9 levels measured on day 1 postadmission. HF events included in‐hospital HF events after the initial presentation and long‐term HF events after discharge. The median follow‐up for the discovery cohort, validation cohort 1, and validation cohort 2 was 4.2, 2.6, and 1.8 years, respectively. In the discovery cohort, S100A8/A9's predictive ability at day 1 surpassed other time points. Through the S100A8/A9‐guided risk stratification, patients deemed high risk (>7900 ng/mL) exhibited a higher 1‐year HF event rate (46% versus 2%, 38% versus 5%) than patients at low risk (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Anzhen Hospital of Capital Medical University Beijing China.
- Beijing Institute of Heart Lung and Blood Vessel Diseases Beijing China.
- Department of Preventive Medicine, Feinberg School of Medicine Northwestern University Chicago IL USA.
- Department of Emergency Medicine Thomas Jefferson University Philadelphia PA USA.
ORCID-Profile: Jie Ma, Ke Ma, Jing Chen, Hui Zhang, Xin-Liang Ma, Yulin Li
Zitieren
APA
Ma, J., Ma, K., Chen, J., Yang, X., Gao, F., Gao, H., Zhang, H., Ma, X. L., Du, J., Li, P., & Li, Y. (2025). Development and Validation of Risk Stratification for Heart Failure After Acute Coronary Syndrome Based on Dynamic S100A8/A9 Levels. Journal of the American Heart Association, 14(3). https://doi.org/10.1161/jaha.124.037401
Vancouver
Ma J, Ma K, Chen J, Yang X, Gao F, Gao H, et al. Development and Validation of Risk Stratification for Heart Failure After Acute Coronary Syndrome Based on Dynamic S100A8/A9 Levels. Journal of the American Heart Association. 2025;14(3). doi:10.1161/jaha.124.037401
BibTeX
@article{Ma2025,
author = {Ma, Jie and Ma, Ke and Chen, Jing and Yang, Xinying and Gao, Fei and Gao, Hai and Zhang, Hui and Ma, Xin-Liang and Du, Jie and Li, Ping and Li, Yulin},
title = {Development and Validation of Risk Stratification for Heart Failure After Acute Coronary Syndrome Based on Dynamic S100A8/A9 Levels},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {3},
doi = {10.1161/jaha.124.037401}
}
EUVIMED